Baxter International (NYSE:BAX) is set to release its earnings data before the market opens on Thursday, July 29th. Analysts expect Baxter International to post earnings of $0.74 per share for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.
Baxter International (NYSE:BAX) last issued its earnings results on Wednesday, April 28th. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.12. The business had revenue of $2.95 billion for the quarter, compared to analyst estimates of $2.89 billion. Baxter International had a net margin of 9.04% and a return on equity of 18.34%. The company's revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.82 EPS. On average, analysts expect Baxter International to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Shares of Baxter International stock opened at $80.27 on Thursday. The firm has a market cap of $40.36 billion, a price-to-earnings ratio of 38.59, a PEG ratio of 2.36 and a beta of 0.68. The firm has a 50-day moving average of $81.80. The company has a current ratio of 2.46, a quick ratio of 1.83 and a debt-to-equity ratio of 0.67. Baxter International has a 1 year low of $74.79 and a 1 year high of $91.45.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 1st. Stockholders of record on Friday, September 3rd will be paid a $0.28 dividend. The ex-dividend date of this dividend is Thursday, September 2nd. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.40%. Baxter International's dividend payout ratio (DPR) is presently 36.25%.
A number of brokerages have recently issued reports on BAX. upped their target price on shares of Baxter International from $94.00 to $98.00 and gave the company a "buy" rating in a research note on Friday, April 30th. Citigroup upped their target price on shares of Baxter International from $94.00 to $98.00 in a research note on Friday, April 30th. Barclays began coverage on shares of Baxter International in a research note on Monday, May 24th. They issued an "equal weight" rating and a $93.00 target price on the stock. Finally, Piper Sandler upped their target price on shares of Baxter International from $80.00 to $85.00 and gave the company an "in-line" rating in a research note on Thursday, April 29th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Baxter International has an average rating of "Buy" and a consensus price target of $90.55.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Recommended Story: What is the CAC 40 Index?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Baxter International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.
While Baxter International currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here